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OBJECTIVE—Pulse pressure (PP), an estimate of arterial stiffness, has been shown to be
associated with incident cardiovascular disease (CVD) in patients with type 1 diabetes (T1D).
However, diabetic kidney disease, a strong predictor of CVD, was not previously taken into
account. Furthermore, the role of PP as a predictor of diabetic nephropathy is not known.
Therefore, we prospectively investigated the associations between PP and these diabetes com-
plications in patients with T1D.
RESEARCH DESIGN AND METHODS—A total of 4,509 patients from the FinnDiane
Study participated. Follow-up data on incident CVD events and renal status (median 5.3 years)
wereavailablein69and76%ofthepatients,respectively.Altogether,269patients(8.6%)hadan
incident CVD event and 370 patients (10.8%) progressed to a higher level of albuminuria or to
end-stage renal disease.
RESULTS—PP was higher at baseline in patients who experienced a CVD event (66 6 18 vs.
52614mmHg;P,0.001)or progressedintheirrenalstatus(58618 vs.54615mmHg;P,
0.01) during follow-up. In a Cox regression model, PP was independently associated with a ﬁrst
ever CVD event (hazard ratio per 10 mmHg 1.22 [95% CI 1.10–1.34]) but not progression of
renal disease (1.00 [0.89–1.12]) after adjustments for traditional risk factors.
CONCLUSIONS—PP, a marker of arterial stiffness, is a risk factor for cardiovascular com-
plications but not for diabetic nephropathy in patients with T1D.
Diabetes Care 34:886–891, 2011
W
hereas systolic blood pressure
(SBP) increases with age in the
western population, diastolic
blood pressure (DBP) generally increases
during adulthood, peaks at 55–60 years
of age, and thereafter starts to decrease as
the result of arterial stiffening (1). This
results in an increased pulse pressure
(PP)that isassociatedwithcardiovascular
disease (CVD) (2). We have shown a pre-
mature increase in PP in patients with
type 1 diabetes (T1D) compared with
nondiabetic subjects (3). The results in-
dicatedanacceleratedarterialaginginpa-
tients with T1D that may contribute to a
higher risk of CVD.
PP has been shown to be a strong
predictor of CVD in the general popula-
tion, especially in elderly subjects aged
.65 years (4,5). The EURODIAB Pro-
spective Complications Study extended
this ﬁnding to patients with T1D because
PP was shown to be associated with in-
cident CVD (6). However, diabetic
nephropathy, a strong CVD risk factor
(7), was not taken into account. Further-
more, Soedamah-Muthu et al. (8) reported
that PP predicted all-cause but not cardio-
vascular mortality in the same cohort.
Although PP was shown to be associ-
atedwithdiabeticnephropathyinacross-
sectional study (3), it is not known
whether PP could be used as a predictor
of progression of diabetic nephropathy.
However, blood pressure per se has
beenshownto predict incipientandovert
diabetic nephropathy, although the re-
sults have been conﬂicting (9–11).
Therefore, the aim was to explore the
role of PP inthe development of CVDand
progression of diabetic nephropathy in a
large, homogeneous and nationwide co-
hort of patients with T1D.
RESEARCH DESIGN AND
METHODS—TheFinnish DiabeticNe-
phropathy (FinnDiane) Study is an ongo-
ing, nationwide, prospective multicenter
study seeking clinical, genetic, biochem-
ical, and environmental risk factors for
diabetes complications, with an emphasis
on diabetic nephropathy. Participating
study centers comprisediabetesand renal
outpatient clinics at all ﬁve university
central hospitals, all 16 central hospitals,
the majority (N = 27) of regional hospi-
tals, and 31 major primary health care
centers in Finland. Patients with T1D (In-
ternational Classiﬁcation of Diseases,
10th Revision, code E10) were recruited
at routine outpatient visits. On the basis
of medical records, the attending physi-
cian completed a standardized check-list
regarding diabetes complications and
medication. Follow-up data have been
collected since 2004 (7). The study pro-
t o c o li si na c c o r d a n c ew i t ht h eD e c l a r a -
tion of Helsinki as revised in 2000 and
approved by the local ethics committee
in each study center. Written informed
consent was obtained from each patient.
At baseline, patients underwent a
thorough clinical investigation that took
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ORIGINAL ARTICLEplaceinconjunctionwitharegularvisitto
theattendingphysician.Patientswithcom-
plete information on clinical data were
selected.Follow-updataontheoccurrence
of CVD and veriﬁed renal status were
collected by reexamination of the patients
or review of the medical ﬁles. The median
(range) follow-up time for the study pop-
ulation was 5.3 (0.0–14.0) years.
Blood pressure was measured by
standard methods. After the patient had
rested for at least 10 min, blood pressure
was measured twice in a sitting position
by a trained nurse. The mean of the two
recordings was used in the analyses. PP
w a sc a l c u l a t e da s( S B P2 DBP in mmHg),
and mean arterial pressure was calculated
as (1/3 SBP + 2/3 DBP in mmHg).
Diabetes complications
CVD was deﬁned as any of the following
events: myocardial infarction, coronary
artery procedure (bypass surgery or an-
gioplasty), stroke (ischemic or hemor-
rhagic), limb amputation because of
ischemia, or a peripheral artery proce-
dure. Renal status was based on the
urinary albumin excretion rate (AER) in
Table 1—Patient characteristics according to baseline quartiles of pulse pressure
1st 2nd 3rd 4th P value
Age-corrected
P value
Patients (N) 1,145 1,080 1,137 1,147 ——
S e x ( % w o m e n ) 4 25 05 85 6 ,0.001 ,0.001
Age (years) 33 6 93 6 6 10 39 6 12 47 6 12 ,0.001 —
Duration (years) 17 6 91 9 6 11 22 6 12 30 6 12 ,0.001 ,0.001
Age at onset (years) 16 6 11 17 6 11 17 6 11 17 6 11 0.25 ,0.001
BMI (kg/m
2) 24.6 6 3.7 24.8 6 3.8 25.2 6 3.5 25.5 6 3.7 ,0.001 0.025
HbA1c (%) 8.5 6 1.7 8.4 6 1.5 8.4 6 1.4 8.5 6 1.5 0.16 0.022
Total cholesterol (mmol/L) 4.9 6 1.0 4.9 6 1.0 4.9 6 1.0 5.2 6 1.1 ,0.001 ,0.001
HDL cholesterol (mmol/L) 1.6 6 0.5 1.6 6 0.5 1.6 6 0.6 1.6 6 0.5 0.49 0.073
LDL cholesterol (mmol/L) 3.0 6 0.8 3.0 6 1.1 3.0 6 0.9 3.2 6 0.9 ,0.001 0.159
Triacylglycerol (mmol/L) 1.02 (0.77–1.43) 1.00 (0.75–1.41) 1.04 (0.77–1.46) 1.10 (0.81–1.58) 0.03 ,0.001
Insulin dose (IU/kg) 0.74 6 0.26 0.72 6 0.26 0.70 6 0.25 0.66 6 0.24 ,0.001 0.005
SBP (mmHg) 118 6 10 127 6 10 136 6 11 156 6 16 ,0.001 ,0.001
DBP (mmHg) 80 6 98 0 6 10 79 6 10 79 6 11 0.39 0.022
PP (mmHg) 38 6 54 8 6 25 7 6 37 6 6 12 ,0.001 ,0.001
Mean arterial pressure (mmHg) 80 6 98 2 6 10 85 6 10 92 6 11 ,0.001 ,0.001
History of CVD (%) 4 6 7 19 ,0.001 ,0.001
History of smoking (%) 47 45 47 50 0.109 0.241
Antihypertensive medication (%) 24 28 38 62 ,0.001 ,0.001
eGFR (mL/min/1.73 m
2)9 2 6 30 93 6 31 90 6 34 87 6 34 ,0.001 ,0.001
Diabetic nephropathy (%) 13 15 20 40 ,0.001 ,0.001
Values are expressed as means 6 SD, percent, or median (interquartile range). eGFR, estimated glomerular ﬁltration rate.
Table 2—Baseline characteristics according to occurrence of an incident CVD event (coronary event, stroke, peripheral vascular event)
and progression in renal status (deﬁned as any increase in albuminuria level or progression to ESRD) during follow-up
Incident CVD event Progression in renal status
Event No event Progressors Nonprogressors
N 269 2,698 373 2,830
Age (years) 49 6 10* 37 6 12 39 6 12 38 6 13
Age at onset (years) 17 6 11 17 6 11 15 6 11† 17 6 11
HbA1c (%) 8.8 6 1.6* 8.4 6 1.5 9.4 6 1.7† 8.3 6 1.4
Total cholesterol (mmol/L) 5.3 6 1.2* 4.9 6 0.9 5.4 6 1.3† 4.9 6 0.9
SBP (mmHg) 148 6 20* 132 6 17 141 6 21† 132 6 17
DBP (mmHg) 81 6 10* 79 6 10 83 6 10† 79 6 10
PP (mmHg) 66 6 18* 52 6 14 58 6 18† 54 6 15
Mean arterial pressure (mmHg) 90 6 10* 83 6 98 9 6 10† 83 6 9
History of CVD (%) 34* 5 12† 7
History of smoking (%) 60* 40 61† 39
Antihypertensive medication (%) 77* 31 60† 35
eGFR (mL/min/1.73 m
2)5 7 6 33* 90 6 31 68 6 41† 88 6 32
Diabetic nephropathy 59* 15 NA NA
Values are expressed as number, means 6 SD, or percentage. Patients with a kidney transplant are excluded from the CVD analysis. eGFR, estimated glomerular
ﬁltration rate; NA, not applicable. *P , 0.05 vs. no event. †P , 0.05 vs. nonprogressors.
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Gordin and Associatestwo of three consecutive overnight or
24-h urine collections. Normal AER was
deﬁned as ,20 mg/min or ,30 mg/24 h,
microalbuminuria was deﬁned as 20 mg/
min # AER ,200 mg/min or 30 mg/24 h
# AER ,300 mg/24 h, and macroalbu-
minuria was deﬁned as AER $200 mg/
min or AER $300 mg/24 h. End-stage
renal disease (ESRD) was deﬁned as pa-
tients undergoing dialysis or having
received a kidney transplant. Progression
was deﬁned as a change from one level
to a higher level of AER or the develop-
ment of ESRD. Diabetic nephropathy was
deﬁned as macroalbuminuria or ESRD.
Patients with akidneytransplantwere ex-
cluded from the CVD analysis. Data on
C V De v e n t sa n dp r o g r e s s i o no fa l b u m i n -
uriawereavailablein3,110patients(69%
of all patients with data on PP) versus
3,424 patients (76%), respectively.
Arterial stiffness by pulse-wave
analysis
In a subpopulation of 408 patients, both
arterial stiffness measured by pulse-wave
analysis (PWA) and follow-up data were
available. The median (range) follow-up
timewas6.1(0.0–11.0)years.Applanation
tonometry(SphygmoCor,Atcor Medical,
Sydney, Australia) is a widely used non-
invasive method to estimate arterial stiff-
ness by analyzing arterial pressure
waveforms (12). The pulse wave was re-
corded from the radial artery of the right
armwithahigh-ﬁdelitymicromanometer
(SPT-301, Millar Instruments, Houston,
TX). A model of the central pressure wave-
form was synthesized by the SphygmoCor
software using a validated generalized
mathematic transformation to calculate
the augmentation index (AIx) and aortic
PP as indicators of arterial stiffness (13).
Assays
Fasting blood samples were analyzed for
HbA1c, serum lipids, and lipoproteins.
HbA1c was determined locally by stan-
dardized assays, and serum lipid and
lipoprotein concentrations were deter-
mined centrally by automated enzymatic
methods (Hoffman-LaRoche, Basel, Swit-
zerland). Estimated glomerular ﬁltration
ratewascalculatedusingtheModiﬁcation
of Diet in Renal Disease four-variable
equation (14,15). AER was assessed
from an overnight or a 24-h urine collec-
tion by immunoturbidimetry.
Statistical analyses
All analyses were performed with SPSS
17.0.1 (SPSS Inc., Chicago, IL). Baseline
characteristics are presented as means 6
SD for normally distributed values and as
median with interquartile range for non-
normally distributed values and percent-
ages. Differences between groups for
normallydistributedvariablesweretested
using ANOVA, and for nonparametric
data the Mann–Whitney or Kruskal–
Wallis test was used. When P values
were adjusted for age, ANCOVA was
used for continuous variables and logistic
regression for categoric variables. For cat-
egoric variables, the x
2 test was used
when appropriate. Risk factors for the
Figure 1—A: Age-adjusted survival curves for an incident CVD event (coronary event, stroke,
peripheralvascularevent) byquartiles of PP.B:Age-adjustedsurvivalcurvesfor any progression
inrenalstatus(deﬁnedasanyincreaseinalbuminurialevel or progression toESRD)by quartiles
of PP.
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were assessed using Cox proportional
hazard survival regression showing re-
sults as hazard ratios with 95% CIs. Age,
sex, HbA1c, total cholesterol, estimated
glomerular ﬁltration rate, history of
smoking,use ofantihypertensive medica-
tion, and PP were used as covariates. To
accountforapotentialmulticolinearity,we
chose to use age but not duration of diabe-
tes in the models, because the associations
were stronger between age at baseline and
incident events at follow-up. Similarly, to-
talcholesterolwaschosenofthecholesterol
indices. SBP was not included in the anal-
ysis because of the strong association with
PP (r =0 . 8 3 ;P , 0.001.)
RESULTS—Altogether, 4,509 patients
werestudied,52%ofwhomweremale.At
baseline their mean age was 39 6 12
years, SBP was 134 6 19 mmHg, DBP
was 80 6 10 mmHg, PP was 55 6 16
mmHg, and HbA1c was 8.5 6 1.5%. A
total of 2,763 patients had normal AER,
561 patients had microalbuminuria, 611
patients had macroalbuminuria, 292 pa-
tients had ESRD, and 282 patients could
notbeclassiﬁedwithrespecttotheirrenal
status because of insufﬁcient number of
urine collections or disease duration ,15
years. At baseline, 9% of patients had
experienced a CVD event. Table 1 shows
patient characteristics according to base-
line quartiles of PP.
A total of 269 patients (8.6%) had an
incident CVD event during follow-up. Of
those, 178 had their ﬁrst ever CVD event.
Altogether, 370 patients (10.8%) pro-
gressed to a higher level of albuminuria
or to ESRD during follow-up (148 to
microalbuminuria, 75 to macroalbumin-
uria, and 147 to ESRD). Table 2 demon-
strates baseline characteristics according
to outcomes during follow-up.
Survival plots
Age-adjustedsurvivalcurvesdemonstratea
positive association between PP and the
occurrence of an incident hard CVD event
during follow-up (Fig. 1A). Thus, patients
in the highest PP quartiles (third and
fourth) more often had a CVD event than
those in the ﬁrst and second quartiles. No
association was observed between PP and
the progression in renal status (Fig. 1B).
Multivariate models
Becauseofthehighproportionofpatients
with a previous CVD event at baseline,
onlypatientswhohadtheirﬁrsteverCVD
event (N = 178) during follow-up (Table
3 )w e r ei n c l u d e di nt h eC o xr e g r e s s i o n
analysis. PP independently predicted a
ﬁrst ever CVD event. Inclusion of AER
or diabetic nephropathy into the model
did not change the results.
PP did not predict progression of renal
disease. Furthermore,noassociations were
observed between PP and progression to
microalbuminuria, macroalbuminuria, or
ESRD when analyzed separately.
After dividing the patients by albu-
minuria at baseline, a similar Cox regres-
sion analysis was performed (Table 4).
The number of ﬁrst ever CVD events at
follow-up was 51 in patientswith normal
AER, 27 in patients with microalbumin-
uria, and 77 in patients with macroal-
buminuria. PP and age independently
predicted a ﬁrst ever CVD event at follow-
up in all groups.
Arterial stiffness by PWA and
incident CVD
Of the 408 patients with PWA data avail-
able, 35 had an incident CVD event
during follow-up. Both aortic PP (61 6
21 vs. 46 6 18 mmHg, P , 0.001) and
AIx (24.3 6 9.0 vs. 19.5 6 12.1%, P ,
0.05) were increased in the patients with
an incident CVD event. Similarly, age
(61 6 21 vs. 46 6 18 years, P , 0.001),
brachial SBP (151 6 23 vs. 137 6 22
mmHg, P , 0.001), and brachial PP
(75 6 21 vs. 63 6 17 mmHg, P ,
0.001) were higher in the patients with a
CVD event. A larger proportion of the pa-
tients with an incident CVD event had di-
abetic nephropathy (57 vs. 37%, P ,
0.001) and previous CVD events (80 vs.
7%, P , 0.001) at baseline.
Aortic PP was independently associ-
ated with incident CVD events during
follow-up (1.29 [1.02–1.62] per 10
mmHg, P = 0.03) after adjusting for age,
sex, total cholesterol, HbA1c,d i a b e t i cn e -
phropathy, and history of smoking in the
Cox model. However, after inclusion of
previous CVD in the model, aortic PP
was no longer a predictor. Finally, AIx
was not independently associated with
anincidentCVDeventinasimilarmodel.
CONCLUSIONS—The main ﬁnding
of this study was that PP predicted a ﬁrst
everCVDeventevenafteradjustmentsfor
renal disease in patients with T1D. An-
other novel ﬁnding was that PP also pre-
dicted incident CVD in diabetic patients
irrespectively of the degree of diabetic
nephropathy.Notably,PPdidnotinﬂuence
the progression of diabetic nephropathy.
We previously showed a premature
increase in PP in patients with T1D
compared with nondiabetic control sub-
jects (3). However, because of the cross-
sectional design of that study, we could
not answer the question whether an early
increase in PP also increased the risk for
CVD in these patients. The current study,
on the other hand, shows that PP indeed
increases the risk for a ﬁrst ever CVD
eventinthesepatients.Thisriskincreased
by 18–41% (per 10 mmHg PP) depend-
ing on renal status.
Table 3—Cox regression analysis for an incident CVD event (coronary event, stroke, peripheral vascular event) and progression in
renal status (deﬁned as any increase in albuminuria level or progression to ESRD)
Incident CVD event Progression in renal status
HR (95% CI) P value HR (95% CI) P value
Age (years) 1.06 (1.04–1.08) ,0.001 1.00 (0.99–1.02) 0.81
Male sex 1.11 (0.79–1.54) 0.55 2.01 (1.47–2.76) ,0.001
HbA1c (%) 1.06 (0.95–1.18) 0.32 1.41 (1.30–1.53) ,0.001
Total cholesterol (mmol/L) 1.26 (1.10–1.45) 0.001 1.19 (1.04–1.37) 0.01
eGFR (mL/min/1.73 m
2) 0.99 (0.98–0.99) ,0.001 1.00 (0.99–1.01) 0.88
History of smoking 1.45 (1.20–1.59) 0.001 1.20 (0.92–1.41) 0.15
Antihypertensive medication 0.43 (0.31–0.71) ,0.001 0.58 (0.42–0.81) 0.001
PP (per 10 mmHg) 1.22 (1.10–1.34) ,0.001 1.00 (0.89–1.12) 0.96
Variables are from baseline. eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio.
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showing PP to be a predictor of CVD in
patients with diabetes. In the Hoorn
Study, PP correlated positively with car-
diovascular mortality (16). However, de-
spitethelargestudysample(N=2,484),it
included no more than 208 patients with
type 2 diabetes. Cockcroft et al. (17) re-
ported PP to predict coronary heart dis-
ease in a large-scale study of patients with
type 2 diabetes. In T1D, results from the
EURODIAB cohort showed PP to associ-
ate with incident CVD after correcting for
age and sex in a multivariate model (6).
However, the association was not inde-
pendent of further adjustments. Notably,
diabetic kidney disease was not included
in the prospective analysis. This is impor-
tant because the presence and severity of
diabetic nephropathy are shown to be
strongly linked to the excess mortality as-
sociated with T1D (7). Moreover, we in-
c l u d e do n l yp a t i e n t sw i t hh a r dC V D
events(coronaryevent,stroke, peripheral
vascular event) in the analysis, whereas
patients with electrocardiogram abnor-
malities and angina pectoris were in-
cluded in the EURODIAB study.
We did not observe an association
between PP and progression in renal
status. To our knowledge, there are no
other prospective studies on PP and di-
abetic nephropathy in T1D in the litera-
ture, but blood pressure per se has been
demonstrated to play a role in the devel-
opment of microvascular complications
(18). Mean arterial pressure predicted the
development of microalbuminuria and
macroalbuminuria in patients with T1D
fromtheStenoDiabetesCenter(10).Sim-
ilar results have been reported by the
Microalbuminuria Collaborative Study
Group (19). Notably, there are also data
available demonstrating no difference in
blood pressure in patients who progress
in renal status and those who do not
(9,11,20).
The data in the small subset of pa-
tients in whom PWA was measured sup-
port the ﬁndings. We recently showed
thatcentralPPismorestronglyassociated
with CVD than AIx in patients with T1D
in the FinnDiane cohort (21). Therefore,
it was not surprising that central PP was
associated with incident CVD in this pro-
spective analysis. The data are further
supported by Roman et al. (22), who re-
ported central PP to be a strong predictor
of incident CVD in a large-scale study.
This study cannot provide the mech-
anisms behind the relationship between
arterial stiffness and CVD events. How-
ever, as the arteries stiffen, less energy is
absorbed during the systolic cardiac
phase and released during the diastolic
phase (23). The phenomenon results in
increased aortic stiffness, increased left
ventricular afterload, increased LV mass
and oxygen demand, and decreased
stroke volume, and consequently poten-
tiates the development of arterial disease
(24). The increase in brachial PP can be
considered a robust measure of arterial
stiffness, especially in older subjects
(5,25). Because the increase in PP occurs
15to20yearsearlierinpatientswithT1D
and is indicative of accelerated vascular
aging, PP may be used as a predictor of
future CVD events in these patients (3).
The strengths of this study are the large
number of well-characterized patients and
the prospective study design. The Finn-
Diane represents a homogenous, nation-
wide cohort of adults with T1D studied
between1997 and2010. A limitationis that
thebloodpressurerecordingswereobtained
on a single occasion. However, if anything,
this only would dilute our ﬁndings.
In view of the combined results, PP, a
marker of arterial stiffness, is a risk factor
for cardiovascular complications but not
for diabetic nephropathy in patients with
T1D.
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